Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
?

?

-1.750%
-0.25
-1.750%
-
 
08:56 / Stuttgart Stock Exchange WKN: A2N9MM / Name: Marinomed Biotech / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Marinomed Biotech AG Stock

A loss of -1.750% shows a downward development for Marinomed Biotech AG.
Our community identified positive and negative aspects for Marinomed Biotech AG stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Marinomed Biotech AG stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

Pros and Cons of Marinomed Biotech AG in the next few years

Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Marinomed Biotech Announces Capital increase with subscription rights
Marinomed Biotech Announces Capital increase with subscription rights
Marinomed Biotech Announces Capital increase with subscription rights
EQS-Adhoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
EQS-Adhoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
EQS-Adhoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform